

HB 0247

2004

1 A bill to be entitled
 2 An act relating to the sale of products containing
 3 ephedrine or ephedra; amending s. 499.033, F.S.;
 4 prohibiting the sale or delivery of products containing
 5 ephedrine or ephedra over the counter without a
 6 prescription, subject to certain exceptions, for which
 7 there are penalties; providing rulemaking authority;
 8 providing an effective date.

9
 10 Be It Enacted by the Legislature of the State of Florida:

11
 12 Section 1. Section 499.033, Florida Statutes, is amended
 13 to read:

14 499.033 Ephedrine; prescription required.--Ephedrine is
 15 declared to be a prescription drug.

16 (1) Except as provided in subsection (2), a person may not
 17 sell or deliver over the counter without a prescription any
 18 product that contains any quantity of ephedrine or ephedra, a
 19 salt of ephedrine, an optical isomer of ephedrine, or a salt of
 20 any optical isomer of ephedrine. Any product that contains any
 21 quantity of ephedrine or ephedra, a salt of ephedrine, an
 22 optical isomer of ephedrine, or a salt of an optical isomer of
 23 ephedrine may be dispensed only upon the prescription of a duly
 24 licensed practitioner authorized by the laws of the state to
 25 prescribe medicinal drugs.

26 (2) A product containing ephedrine described in paragraphs
 27 (a)-(e) is exempt from subsection (1) if it may lawfully be sold
 28 over the counter without a prescription under the federal act;
 29 is labeled and marketed in a manner consistent with the

HB 0247

2004

30 pertinent United States Food and Drug Administration Over-the-
 31 Counter Tentative Final or Final Monograph; and is manufactured
 32 and distributed for legitimate medicinal use in a manner that
 33 reduces or eliminates the likelihood of abuse, when considered
 34 in the context with: the package sizes and the manner of
 35 packaging of the drug product; the name and labeling of the
 36 product; the manner of distribution, advertising, and promotion
 37 of the product; the duration, scope, health significance, and
 38 societal cost of abuse of the particular product; the need to
 39 provide medically important ephedrine-containing therapies to
 40 the public for United States Food and Drug Administration
 41 approved indications on an unrestricted, over-the-counter basis;
 42 and other facts as may be relevant to and consistent with public
 43 health and safety.

44 (a) Solid oral dosage forms that combine active
 45 ingredients in the following ranges for each dosage unit:

- 46 1. Theophylline (100-130mg), ephedrine (12.5-24mg).
- 47 2. Theophylline (60-100mg), ephedrine (12.5-24mg),
 48 guaifenesin(200-400mg).
- 49 3. Ephedrine (12.5-25mg), guaifenesin (200-400mg).
- 50 4. Phenobarbital (not greater than 8mg) in combination
 51 with the ingredients of subparagraph 1. or subparagraph 2.

52 (b) Liquid oral dosage forms that combine active
 53 ingredients in the following ranges for each (5ml) dose:

- 54 1. Theophylline (not greater than 45mg), ephedrine (not
 55 greater than 36mg), guaifenesin (not greater than 100mg),
 56 phenobarbital (not greater than 12mg).
- 57 2. Phenylephrine (not greater than 5mg), ephedrine (not
 58 greater than 5mg), chlorpheniramine (not greater than 2mg),

HB 0247

2004

59 dextromethorphan (not greater than 10mg), ammonium chloride (not
60 greater than 40mg), ipecac fluid extract (not greater than
61 0.005ml).

62 (c) Anorectal preparations containing less than 5 percent
63 ephedrine.

64 (d) Nasal decongestant compounds, mixtures, or
65 preparations containing 0.5 percent or less ephedrine.

66 (e) Any drug product containing ephedrine that is marketed
67 pursuant to an approved new drug application or legal equivalent
68 under the federal act.

69 (3) The department may administer ~~implement~~ this section
70 by rule.

71 Section 2. This act shall take effect July 1, 2004.